Citius Pharmaceuticals Stock Buy Hold or Sell Recommendation
| CTXR Stock | USD 0.82 0.07 9.33% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Citius Pharmaceuticals is 'Cautious Hold'. Macroaxis provides Citius Pharmaceuticals buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding CTXR positions. The advice algorithm takes into account all of Citius Pharmaceuticals' available fundamental, technical, and predictive indicators you will find on this site. Key drivers impacting Citius Pharmaceuticals' buy or sell advice are summarized below:
Real Value 1.91 | Target Price 5.33 | Hype Value 0.81 | Market Value 0.82 |
A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Citius Pharmaceuticals given historical horizon and risk tolerance towards Citius Pharmaceuticals. When Macroaxis issues a 'buy' or 'sell' recommendation for Citius Pharmaceuticals, the advice is generated through an automated system that utilizes algorithms and statistical models.
Citius |
Execute Citius Pharmaceuticals Buy or Sell Advice
The Citius recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Citius Pharmaceuticals. Macroaxis does not own or have any residual interests in Citius Pharmaceuticals or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Citius Pharmaceuticals' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Modest | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Very Weak | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Citius Pharmaceuticals Trading Alerts and Improvement Suggestions
| Citius Pharmaceuticals had very high historical volatility over the last 90 days | |
| Citius Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Net Loss for the year was (32.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Citius Pharmaceuticals currently holds about 48.04 M in cash with (29.06 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.33. | |
| Citius Pharmaceuticals has a very weak financial position based on the latest SEC disclosures | |
| Latest headline from benzinga.com: Citius Pharmaceuticals Advances Oncology Asset, Paving Way For Spin Out Of Advanced T-cell Lymphoma Treatment |
Citius Pharmaceuticals Returns Distribution Density
The distribution of Citius Pharmaceuticals' historical returns is an attempt to chart the uncertainty of Citius Pharmaceuticals' future price movements. The chart of the probability distribution of Citius Pharmaceuticals daily returns describes the distribution of returns around its average expected value. We use Citius Pharmaceuticals price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Citius Pharmaceuticals returns is essential to provide solid investment advice for Citius Pharmaceuticals.
| Mean Return | 0.25 | Value At Risk | -5.56 | Potential Upside | 9.33 | Standard Deviation | 4.95 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Citius Pharmaceuticals historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Citius Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Citius Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Citius Pharmaceuticals backward and forwards among themselves. Citius Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Citius Pharmaceuticals' securities or originates loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Goldman Sachs Group Inc | 2023-12-31 | 185.1 K | Inspire Advisors, Llc | 2023-12-31 | 182.7 K | Bank Of America Corp | 2023-12-31 | 180.6 K | Barclays Plc | 2023-12-31 | 168.8 K | Key Bridge Compliance Llc | 2023-09-30 | 154.1 K | Rhumbline Advisers | 2023-12-31 | 150.1 K | Susquehanna International Group, Llp | 2023-12-31 | 141 K | Ubs Group Ag | 2023-12-31 | 137.5 K | Arkadios Wealth Advisors | 2023-12-31 | 100 K | Blackrock Inc | 2023-12-31 | 8.5 M | Vanguard Group Inc | 2023-12-31 | 6.9 M |
Citius Pharmaceuticals Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 6.0M | 56.2M | (28.4M) | (15.2M) | (17.5M) | (16.6M) | |
| Free Cash Flow | (16.9M) | (64.3M) | (28.4M) | (29.1M) | (26.2M) | (24.8M) | |
| Other Non Cash Items | 528.8K | 68K | 378.2K | 102K | 117.3K | 111.4K | |
| Net Income | (17.5M) | (23.1M) | (33.6M) | (32.5M) | (29.3M) | (27.8M) | |
| End Period Cash Flow | 13.9M | 70.1M | 41.7M | 26.5M | 30.5M | 16.0M | |
| Change To Netincome | 716.0K | 803.3K | 1.3M | 4.5M | 5.2M | 5.4M | |
| Depreciation | 152.4K | 164.9K | 179.7K | 194.3K | 223.5K | 234.6K | |
| Change Receivables | (802.7K) | 834.8K | 15.7K | (88.0K) | (101.2K) | (96.1K) |
Citius Pharmaceuticals Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Citius Pharmaceuticals or Pharmaceuticals sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Citius Pharmaceuticals' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Citius stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over NYSE Composite | 0.12 | |
β | Beta against NYSE Composite | 2.72 | |
σ | Overall volatility | 5.02 | |
Ir | Information ratio | 0.04 |
Citius Pharmaceuticals Volatility Alert
Citius Pharmaceuticals shows above-average downside volatility for the selected time horizon. Citius Pharmaceuticals is a potential penny stock. Although Citius Pharmaceuticals may be in fact a good instrument to invest, many penny stocks are speculative in nature and are subject to artificial price hype. Please make sure you totally understand the upside potential and downside risk of investing in Citius Pharmaceuticals. We encourage investors to look for signals such as email spams, message board hypes, claims of breakthroughs, volume upswings, sudden news releases, promotions that are not reported, or demotions released before SEC filings. Please also check biographies and work history of current and past company officers before investing in high volatility instruments, penny stocks, or equities with microcap classification. You can indeed make money on Citius instrument if you perfectly time your entry and exit. However, remember that penny stocks that have been the subject of artificial hype usually unable to maintain their increased share price for more than just a few days. The price of a promoted high volatility instrument will almost always revert back. The only way to increase shareholder value is through legitimate performance backed up by solid fundamentals.Citius Pharmaceuticals Fundamentals Vs Peers
Comparing Citius Pharmaceuticals' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Citius Pharmaceuticals' direct or indirect competition across all of the common fundamentals between Citius Pharmaceuticals and the related equities. This way, we can detect undervalued stocks with similar characteristics as Citius Pharmaceuticals or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Citius Pharmaceuticals' fundamental indicators could also be used in its relative valuation, which is a method of valuing Citius Pharmaceuticals by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Citius Pharmaceuticals to competition |
| Fundamentals | Citius Pharmaceuticals | Peer Average |
| Return On Equity | -0.41 | -0.31 |
| Return On Asset | -0.23 | -0.14 |
| Current Valuation | 99.97 M | 16.62 B |
| Shares Outstanding | 159.1 M | 571.82 M |
| Shares Owned By Insiders | 7.73 % | 10.09 % |
| Shares Owned By Institutions | 17.01 % | 39.21 % |
| Number Of Shares Shorted | 12.43 M | 4.71 M |
| Price To Earning | (1.34) X | 28.72 X |
| Price To Book | 1.49 X | 9.51 X |
| EBITDA | (36.54 M) | 3.9 B |
| Net Income | (32.54 M) | 570.98 M |
| Cash And Equivalents | 48.04 M | 2.7 B |
| Cash Per Share | 0.33 X | 5.01 X |
| Total Debt | 481.25 K | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 11.40 X | 2.16 X |
| Book Value Per Share | 0.53 X | 1.93 K |
| Cash Flow From Operations | (29.06 M) | 971.22 M |
| Short Ratio | 20.27 X | 4.00 X |
| Earnings Per Share | (0.26) X | 3.12 X |
| Target Price | 5.33 | |
| Number Of Employees | 22 | 18.84 K |
| Beta | 1.51 | -0.15 |
| Market Capitalization | 119.34 M | 19.03 B |
| Total Asset | 103.61 M | 29.47 B |
| Retained Earnings | (162.23 M) | 9.33 B |
| Working Capital | 28.59 M | 1.48 B |
| Current Asset | 893 K | 9.34 B |
| Current Liabilities | 5.18 M | 7.9 B |
| Net Asset | 103.61 M |
Note: Disposition of 129450 shares by Myron Holubiak of Citius Pharmaceuticals at 1.42 subject to Rule 16b-3 [view details]
Citius Pharmaceuticals Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Citius . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Citius Pharmaceuticals Buy or Sell Advice
When is the right time to buy or sell Citius Pharmaceuticals? Buying financial instruments such as Citius Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.| 2021 | 2022 | 2023 | 2024 (projected) | Short and Long Term Debt Total | 678.2K | 481.2K | 553.4K | 476.4K | Total Assets | 114.0M | 103.6M | 119.2M | 125.1M |
Use Investing Ideas to Build Portfolios
In addition to having Citius Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Artificial Intelligence Thematic Idea Now
Artificial Intelligence
Technology companies, funds, and ETFs across multiple industries that are involved in research or development in the field of reasoning, learning, natural language processing and perception as well as its application to science and commerce. This theme may also include entities involved in cybernetics and cognitive brain simulation field. The Artificial Intelligence theme has 41 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Artificial Intelligence Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Citius Pharmaceuticals Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. To learn how to invest in Citius Stock, please use our How to Invest in Citius Pharmaceuticals guide.You can also try the Financial Widgets module to easily integrated Macroaxis content with over 30 different plug-and-play financial widgets.
Complementary Tools for Citius Stock analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is Citius Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Citius Pharmaceuticals. If investors know Citius will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Citius Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.26) | Return On Assets (0.23) | Return On Equity (0.41) |
The market value of Citius Pharmaceuticals is measured differently than its book value, which is the value of Citius that is recorded on the company's balance sheet. Investors also form their own opinion of Citius Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Citius Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Citius Pharmaceuticals' market value can be influenced by many factors that don't directly affect Citius Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Citius Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Citius Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Citius Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.